Denali Therapeutics Inc.
NASDAQ:DNLI · NASDAQ Global Select
+$0.09 today
Vol 2.52M · Avg 1.84M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:DNLI · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$508.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.88, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $330.5M +204.7% | $108.5M +122.9% | $48.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $11.2M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$11.2M | $0 -100.0% | $330.5M +204.7% | $108.5M +122.9% | $48.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $418.8M +5.6% | $396.4M -6.5% | $423.9M +18.2% | $358.7M +35.2% | $265.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $97.1M -7.9% | $105.4M +2.0% | $103.4M +14.2% | $90.5M +14.4% | $79.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $544.2M +11.7% | $487.3M -7.6% | $527.2M +17.4% | $449.2M +30.4% | $344.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $14.8M +64.7% | $9.0M -46.2% | $16.7M +61.1% | $10.4M +20.8% | $8.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$497.6M -1.0% | -$492.9M -283.7% | -$128.5M +59.3% | -$315.6M -11.7% | -$282.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | -38.9% +252.1pp | -291.0% +289.7pp | -580.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$555.3M -14.0% | -$487.3M -147.8% | -$196.7M +42.3% | -$340.7M -15.2% | -$295.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -59.5% +254.6pp | -314.2% +293.6pp | -607.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $42.9M -33.6% | $64.6M +25.5% | $51.5M +248.6% | $14.8M +221.5% | $4.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $42.9M -33.6% | $64.6M +25.5% | $51.5M +248.6% | $14.8M +221.5% | $4.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$512.4M -21.2% | -$422.7M -191.1% | -$145.2M +55.5% | -$326.0M -12.0% | -$291.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | -43.9% +256.6pp | -300.5% +297.8pp | -598.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $102.0K +50.0% | $68.0K +126.7% | $30.0K +42.9% | $21.0K +103.7% | -$575.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$512.5M -21.2% | -$422.8M -191.1% | -$145.2M +55.5% | -$326.0M -12.2% | -$290.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | -43.9% +256.6pp | -300.6% +296.6pp | -597.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -15.6% | -$3 -142.5% | -$1 +59.2% | -$3 -8.8% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -15.6% | -$3 -142.5% | -$1 +59.2% | -$3 -8.8% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $175.5M +6.7% | $164.5M +19.7% | $137.4M +9.4% | $125.5M +3.3% | $121.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $175.5M +6.7% | $164.5M +19.7% | $137.4M +9.4% | $125.5M +3.3% | $121.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.39B
Liquidia Corporation
NASDAQ:LQDA
$6.10B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.93B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.42B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.44B
89bio, Inc.
ETNB
$2.20B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.01B
Galapagos N.V.
GLPG
$1.84B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.51B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DNLI generate?
Denali Therapeutics Inc. (DNLI) reported $0.00 of revenue in fiscal 2025.
Is DNLI profitable?
Denali Therapeutics Inc. (DNLI) reported -$512,540,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.